A Phase 4 interventional study of Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months. and Two optical coherence tomography (OCT) devices will be used to assess blood flow changes. in Glaucoma, sponsored by Oregon Health and Science University. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.
Sponsored by Oregon Health and Science University · Phase 4, Interventional, and Treatment
The main purpose of this study is to learn more about how Rocklatan eye drops affects blood flow in the eye. The secondary purpose is to see if our study devices can detect changes in blood flow before and after instillation of Rocklatan.
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's planned enrollment of 30 is below the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →Oregon Health and Science University is the lead sponsor of 676 studies on the registry; 136 are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 36 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months. · Device: Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.
This is also an eye with glaucoma, but the control eye will use clinically prescribed medication instead of the study drug.
The eye not selected as the study eye will be used for comparison so both eyes will be imaged with the study devices to assess blood flow changes.
One OCT device is FDA-cleared while the other is still experimental. Both devices assess blood flow in different ways.
Nerve Fiber Layer Plexus Capillary Density (NFLP CD)
The primary outcome measure will be change in the overall peripapillary NFLP CD measured at 6 months and 11-12 month endpoint visits compared to baseline values.
Time frame: From enrollment to end of treatment at 11-12 months
Total Retinal Blood Flow (TRBF)
Secondary outcome measures will include change in the TRBF measured at 6 months or 11-12 month endpoint visits compared to baseline.
Time frame: From enrollment to end of treatment at 11-12 months
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oregon Health and Science University